Amgen Gets Untitled Letter as FDA Steps Up Advertising Enforcement

Drug Industry Daily
Amgen is the latest drugmaker caught up in the FDA’s recent flurry of enforcement letters for false or misleading promotional materials. An ad developed by the company for its anemia drug Aranesp omitted risks and inflated efficacy claims, the agency says.

To View This Article:


Subscribe To Drug Industry Daily